Limitations, agreements, and source contact

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma · Source last updated 2021-11-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

point Of Contact

email

winrich.rauschning@external.morphosys.com

organization

MorphoSys AG

phone

+4989 89927

phone Ext

0

title

Dr Winrich Rauschning, Clinical Project Lead (external)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice